Using exosomes to deliver cancer drugs more effectively
Exosomes as carriers of cancer therapeutics
This study is looking at a new way to help treat lung cancer by using tiny particles called exosomes to deliver cancer-fighting drugs right to the tumors, which could make the treatment work better and cause fewer side effects for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-10927284 on NIH RePORTER |
What this research studies
This research investigates the use of exosomes, which are tiny vesicles derived from cells, as carriers for delivering anticancer drugs specifically to lung tumors. The approach involves loading these exosomes with iron-oxide nanoparticles that carry drugs like Doxorubicin and Cisplatin, allowing for controlled release of the medication directly at the tumor site. By targeting the delivery system to the tumor, the research aims to minimize side effects on healthy cells and improve the overall effectiveness of cancer treatments. The study also includes monitoring tumor growth and treatment response using advanced imaging techniques.
Who could benefit from this research
Good fit: Ideal candidates for this research are lung cancer patients who have not responded well to existing therapies or have experienced relapse.
Not a fit: Patients with early-stage lung cancer or those who are not receiving treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic cancer treatments for lung cancer patients.
How similar studies have performed: Other research has shown promise in using exosomes for drug delivery, indicating potential success for this novel approach.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Ramesh, Rajagopal — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Ramesh, Rajagopal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.